Aspirin as a Treatment for Cancer

Clinical Oncology

Volumn 25, Issue 6, 2013, Pages 333-335

  Phillips, I ^a   Langley, R ^b   Gilbert, D ^a   Ring, A ^c  

^a ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA CATENIN; CASPASE 9; CERAMIDE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME C; ESOMEPRAZOLE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; SURVIVIN; TUMOR NECROSIS FACTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BARRETT ESOPHAGUS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; COLORECTAL CANCER; DISTANT METASTASIS; DOWN REGULATION; DRUG BINDING; EDITORIAL; ESOPHAGUS CANCER; HUMAN; LOW DRUG DOSE; LUNG CANCER; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; STOMACH CANCER; THROMBOCYTE AGGREGATION; WNT SIGNALING PATHWAY;

ASPIRIN; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84877143409     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.03.001     Document Type: Editorial

References (20)

1. Langley R., Tierney J., Cafferty F., Parmar M., Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?. Br J Cancer 2011, 105:1107-1112.
2. Add-aspirin trial. MRC Clinical Trials Unit. E-mail. mailto:Add-Aspirin@ctu.mrc.ac.uk.
3. Labelle M., Hynes R.O. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer Discov 2012, 2(12):1091-1099.
4. Cha Y.I., DuBois R.N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007, 58:239-252.
5. Liao X., Lochhead P., Nishihara R., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. NEngl J Med 2012, 367(17):1596-1606.
6. Ferrario A., Xu F., Luna M., et al. Enhancement of photodynamic therapy by 2,5-dimethyl celecoxib, a non-cyclooxygenase-2 inhibitor analog of celecoxib. Cancer Lett 2011, 304(1):33-40.
7. Thun M., Jacob E., Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012, 9(5):259-267.
8. Din F.V., Dunlop M.G., Stark L.A. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer 2004, 91(2):381-388.
9. Rothwell P., Fowkes F., Zanchetti A., et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012, 379(9826):1602-1612.
10. Rothwell P., Wilson M., Price J., Belch J., Meade T., Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012, 379(9826):1591-1601.
11. Rothwell P., Belch J., Ogawa H., Warlow C., Meade T. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377(9759):31-41.
12. Bosetti C., Rosato V., Gallus S., Cuzick J., La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012, 23(6):1403-1415.
13. Derry S., Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. Br Med J 2000, 321(7270):1183-1187.
14. Burn J., Gerdes A., Macrae F., et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011, 378(9809):2081-2087.
15. Thiagarajan P., Jankowski J. Aspirin and NSAIDs; benefits and harms for the gut. Best Pract Res Clin Gastroenterol 2012, 26(2):197-206.
16. Chan A.T., Ogino S., Fuchs C. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009, 302(6):649-658.
17. Bastiaannet E., Dekkers O., de Craen A., et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer 2012, 106(9):1564-1570.
18. McCowan C., Donnan P., Steele R. Use of aspirin post-diagnosis in a cohort of patients with colorectal cancer and its association with all-cause and colorectal cancer specific mortality. Eur J Cancer 2013, 49(5):1049-1057.
19. Choe K., Cowan J., Chan J., Carroll P., D'Amico A., Liauw S. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. JClin Oncol 2012, 30(28):3540-3544.
20. Liu J., Jamieson G., Wu T., Zhu G., Drew P. Apreliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. Ann Surg Oncol 2009, 16(5):1397-1402.